Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Cardiac Troponins in Kidney Disease
Author(s): Daniel Murphy , Debasish Banerjee Added: 8 months ago

Cardiovascular Kidney Metabolic

Heart Failure
New Horizons in Cardio Kidney Disease
Author(s): Muthiah Vaduganathan, Neha Pagidipati, Smeeta Sinha Start date: Jun 30, 2026
Join us for New Horizons in Cardio Kidney Disease, a new one-day virtual educational event taking place on 30 June 2026. This programme is designed to address current challenges in cardio-kidney care through practical, cross-disciplinary education, with a focus on biomarker-guided risk assessment, optimisation of blood pressure and cardio-kidney therapies, and emerging multimodal strategies.The… View more

Cardiovascular Kidney Metabolic
Obesity and CKD: The Dual Epidemic in Cardiovascular Health
Author(s): Christopher Henry Grant , Samira Bell Added: 6 months ago

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Staging of Heart Failure with Preserved Ejection Fraction
Author(s): Anastasia Shchendrygina , Ilya Giverts , Mariya Tokmakova , et al Added: 1 year ago

Imaging & Diagnostics

Heart Failure
EMPA-KIDNEY: Empagliflozin in Patients with Chronic Kidney Disease
Author(s): William Herrington Added: 1 year ago
Long-term cardio-renal outcomes investigating empagliflozin (Boehringer Ingelheim) on kidney disease progression (KDP) or cardiovascular death in patients with pre-existing chronic kidney disease.In this short interview, Prof William Herrington (Nuffield Department of Population Health, University of Oxford, Oxford, UK) discusses the findings from EMPA-KIDNEY (NCT03594110).EMPA-KIDNEY is an… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Author(s): Chim C Lang Added: 10 months ago
Prof Chim Lang discusses his upcoming special focus for ECR. The collection will include contributions from Dr Emily Morris, Dr John Wilding, Dr Samira Bell, Dr Bianca Rocca, and Dr Ramzi Ajjan, the collection explores the global burden of obesity, its impact on heart failure and kidney disease, and emerging therapeutic strategies—including the evolving role of GLP-1 receptor agonists. View more

Cardiovascular Kidney Metabolic
Real-World Data for CV and Renal Outcomes in DKD
Author(s): David Wheeler Added: 10 months ago
ERA 2025 - Prof David Wheeler (University College London, London, UK) joins us to discuss outcomes from real-world data investigating cardiovascular and renal outcomes in patients with DKD.Interview Questions:1. How do real-world cardiovascular and renal outcomes compare to clinical trial results, and which data sources are giving us the best insights into DKD outcomes?2. What's the biggest gap… View more

Cardiovascular Kidney Metabolic
Obesity Management and Cardiovascular Disease
Author(s): Miao Gao , Tanjot Singh , Ramzi Ajjan Added: 2 weeks ago

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
ERA 25: eGFR Dips and Disease Severity on Empagliflozin
Author(s): Added: 10 months ago
ERA 2025 - Results from a meta-analysis of trials including EMPA-KIDNEY show the treatment effect of empagliflozin is not modified by level of predicted acute eGFR dip.Dr Natalie Staplin (University of Oxford, Oxford, UK) joins us to discuss findings from a meta-analysis of four trials, including the EMPA-KIDNEY trial (NCT03594110), investigating the impact of acute eGFR dips and markers of… View more

Cardiovascular Kidney Metabolic
OPTION-STEMI: Staged Revascularisation for STEMI with HF
Added: 3 weeks ago Source:  Cardiac Failure Review
The optimal timing for complete revascularisation in patients with ST-segment elevation myocardial infarction (STEMI) and multi-vessel disease who also present with heart failure is a key clinical question. A pre-specified subgroup analysis of the OPTION-STEMI trial suggests that a staged approach may be preferable to immediate complete revascularisation in this high-risk patient group… View more

Intervention

MI/ACS